News | Clinical Decision Support | July 15, 2016

NCCN Accepted as CMS-Approved Provider-Led Entity for Development of Imaging Appropriate Use Criteria

NCCN joins 10 other multidisciplinary organizations as a qualified provider-led entity under the Medicare Appropriate Use Criteria (AUC) program for advanced diagnostic imaging

The National Comprehensive Cancer Network (NCCN), an alliance of 27 of the nation’s leading cancer centers, has been recognized as a qualified provider-led entity (PLE) for the new Medicare Appropriate Use Criteria (AUC) Program by Centers for Medicare & Medicaid Services (CMS). Through this qualification, CMS — the nation’s largest health payer — recognizes NCCN as a group qualified to develop AUC and establish policy and decision-making for diagnostic imaging in patients with cancer. NCCN Imaging AUC are available free of charge to registered users of NCCN.org and can be accessed at NCCN.org/ImagingAUC.

“NCCN is proud of this acknowledgement from CMS, and we congratulate our fellow PLEs on their recognition,” said Robert W. Carlson, M.D., chief executive officer, NCCN. “At NCCN, we strive to improve the lives of people with cancer, and as a CMS-approved provider-led entity for development of diagnostic imaging AUC, we help to further assure that patients with cancer receive quality care while avoiding unnecessary diagnostic imaging.”

Adapted from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), NCCN Imaging AUC support clinical decision-making around the use of imaging in patients with cancer by outlining all imaging procedures recommended in the NCCN Guidelines, including radiographs, computed tomography (CT) scans, magnetic resonance imaging (MRI), functional nuclear medicine imaging (PET, SPECT), and ultrasound. NCCN is committed to assuring that the most up-to-date recommendations are available and reviews and updates the NCCN Imaging AUC™ on a continual basis to ensure that the recommendations take into account the most current evidence.

Today, NCCN Imaging AUC for the following NCCN Guidelines are available:
• Acute Lymphoblastic Leukemia, Version 1.2016
• Acute Myeloid Leukemia, Version 1.2016
• Bladder Cancer, Version 2.2016
• Breast Cancer, Version 2.2016
• Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2016
• Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2016
• Hodgkin Lymphoma, Version 3.2016
• Lung Cancer Screening, Version 2.2016
• Neuroendocrine Tumors, Version 2.2016
• Pancreatic Adenocarcinoma, Version 1.2016
• Prostate Cancer, Version 3.2016
• Prostate Cancer Early Detection, Version 2.2016
NCCN Imaging AUC for additional cancer types will be published in the coming months.

NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. Since June 2008, CMS has recognized the NCCN Drugs & Biologics Compendium (NCCN Compendium) as a mandated reference for establishment of coverage policy and coverage decisions regarding the use of drugs and biologics in cancer care.

For more information: NCCN.org/ImagingAUC

Related Content

RADxx Announces 2nd Annual Award Winners for Outstanding Leadership in Medical Imaging Informatics
News | Radiology Business | December 14, 2018
RAD Women (#RADxx), a networking group for the advancement of women in imaging informatics, recently announced the...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA
News | Mammography | November 21, 2018
Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological...
Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...